JP7598137B2 - 放射線または放射線療法によって引き起こされた放射線誘発性バイスタンダ効果を防止および治療するための組成物および方法 - Google Patents

放射線または放射線療法によって引き起こされた放射線誘発性バイスタンダ効果を防止および治療するための組成物および方法 Download PDF

Info

Publication number
JP7598137B2
JP7598137B2 JP2020502226A JP2020502226A JP7598137B2 JP 7598137 B2 JP7598137 B2 JP 7598137B2 JP 2020502226 A JP2020502226 A JP 2020502226A JP 2020502226 A JP2020502226 A JP 2020502226A JP 7598137 B2 JP7598137 B2 JP 7598137B2
Authority
JP
Japan
Prior art keywords
radiation
cpr
ribe
subject
ctsb
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020502226A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020527569A5 (enExample
JP2020527569A (ja
Inventor
シュエ，ディン
ポン，ユ
ジャン，マン
ジェン，リンジュン
リャン，シャン
リ，ハンツァン
ユ，ジャウ－ソン
チェン，ジェン－ティン
Original Assignee
ザ・リージエンツ・オブ・ザ・ユニバーシテイ・オブ・コロラド、ア・ボデイー・コーポレイト
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ザ・リージエンツ・オブ・ザ・ユニバーシテイ・オブ・コロラド、ア・ボデイー・コーポレイト filed Critical ザ・リージエンツ・オブ・ザ・ユニバーシテイ・オブ・コロラド、ア・ボデイー・コーポレイト
Publication of JP2020527569A publication Critical patent/JP2020527569A/ja
Publication of JP2020527569A5 publication Critical patent/JP2020527569A5/ja
Priority to JP2023061067A priority Critical patent/JP2023093533A/ja
Application granted granted Critical
Publication of JP7598137B2 publication Critical patent/JP7598137B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/336—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having three-membered rings, e.g. oxirane, fumagillin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Toxicology (AREA)
  • Dermatology (AREA)
JP2020502226A 2017-07-17 2018-07-17 放射線または放射線療法によって引き起こされた放射線誘発性バイスタンダ効果を防止および治療するための組成物および方法 Active JP7598137B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023061067A JP2023093533A (ja) 2017-07-17 2023-04-05 放射線または放射線療法によって引き起こされた放射線誘発性バイスタンダ効果を防止および治療するための組成物および方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762533272P 2017-07-17 2017-07-17
US62/533,272 2017-07-17
PCT/US2018/042569 WO2019018451A2 (en) 2017-07-17 2018-07-17 COMPOSITIONS AND METHODS FOR PREVENTING AND TREATING RADIATION-INDUCED PROXIMITY EFFECTS CAUSED BY RADIATION OR RADIATION THERAPY

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023061067A Division JP2023093533A (ja) 2017-07-17 2023-04-05 放射線または放射線療法によって引き起こされた放射線誘発性バイスタンダ効果を防止および治療するための組成物および方法

Publications (3)

Publication Number Publication Date
JP2020527569A JP2020527569A (ja) 2020-09-10
JP2020527569A5 JP2020527569A5 (enExample) 2021-08-26
JP7598137B2 true JP7598137B2 (ja) 2024-12-11

Family

ID=65015329

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020502226A Active JP7598137B2 (ja) 2017-07-17 2018-07-17 放射線または放射線療法によって引き起こされた放射線誘発性バイスタンダ効果を防止および治療するための組成物および方法
JP2023061067A Pending JP2023093533A (ja) 2017-07-17 2023-04-05 放射線または放射線療法によって引き起こされた放射線誘発性バイスタンダ効果を防止および治療するための組成物および方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023061067A Pending JP2023093533A (ja) 2017-07-17 2023-04-05 放射線または放射線療法によって引き起こされた放射線誘発性バイスタンダ効果を防止および治療するための組成物および方法

Country Status (6)

Country Link
US (2) US11452709B2 (enExample)
EP (1) EP3655015B1 (enExample)
JP (2) JP7598137B2 (enExample)
CN (1) CN111447940A (enExample)
CA (1) CA3069701A1 (enExample)
WO (1) WO2019018451A2 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111447940A (zh) 2017-07-17 2020-07-24 科罗拉多大学评议会 预防或治疗由辐射或放射疗法引起的辐射诱发的旁观者效应的组合物和方法
CN112553286A (zh) * 2020-11-05 2021-03-26 北京大学深圳医院 自杀基因/前药系统疗效的评价方法和药物筛选方法
KR102817623B1 (ko) * 2021-05-14 2025-06-10 한국원자력의학원 방사선 치료 예후 예측용 또는 방사선 저항성 암 진단용 바이오마커 조성물
CN114392255A (zh) * 2021-11-10 2022-04-26 甘肃中医药大学 乌拉尔醇的新应用
CN114150054B (zh) * 2021-12-03 2022-08-02 中国科学院近代物理研究所 检测或评估电离辐射损伤或暴露的试剂及其所用tRNA衍生片段
CN114350787B (zh) * 2022-01-12 2023-06-30 中国人民解放军军事科学院军事医学研究院 一种ATE1的RNA m6A修饰作为γ射线辐射标志物的应用
CN119185555B (zh) * 2024-11-27 2025-04-04 浙江大学 一种用于干预捻转血矛线虫群体性别比例的siRNA及应用

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4987071A (en) 1986-12-03 1991-01-22 University Patents, Inc. RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods
US4904582A (en) 1987-06-11 1990-02-27 Synthetic Genetics Novel amphiphilic nucleic acid conjugates
DE3852539T3 (de) 1987-12-15 2005-08-04 Gene Shears Pty. Ltd. Ribozyme.
US5176996A (en) 1988-12-20 1993-01-05 Baylor College Of Medicine Method for making synthetic oligonucleotides which bind specifically to target sites on duplex DNA molecules, by forming a colinear triplex, the synthetic oligonucleotides and methods of use
US5244805A (en) 1989-05-17 1993-09-14 University Of Georgia Research Foundation, Inc. Baculovirus expression vectors
US5256775A (en) 1989-06-05 1993-10-26 Gilead Sciences, Inc. Exonuclease-resistant oligonucleotides
US5264564A (en) 1989-10-24 1993-11-23 Gilead Sciences Oligonucleotide analogs with novel linkages
US5723750A (en) 1995-01-12 1998-03-03 Vanderbilt University Transgenic plants expressing disassembly deficient viral coat proteins
US6278039B1 (en) 1997-05-28 2001-08-21 Axys Pharmaceuticals, Inc. C. elegans deletion mutants
US6251588B1 (en) 1998-02-10 2001-06-26 Agilent Technologies, Inc. Method for evaluating oligonucleotide probe sequences
US6110462A (en) 1999-03-03 2000-08-29 The Scripps Research Institute Enzymatic DNA molecules that contain modified nucleotides
WO2007072225A2 (en) * 2005-12-01 2007-06-28 Medical Prognosis Institute Methods and devices for identifying biomarkers of treatment response and use thereof to predict treatment efficacy
WO2008106463A1 (en) * 2007-02-26 2008-09-04 The Board Of Trustees Of The Univerity Of Illinois Phenylalanine for plant protection against uv radiation
BRPI0907729A2 (pt) * 2008-02-07 2015-07-14 Virobay Inc Métodos para tratar doenças mediadas pela catepsina b em um mamífero e para tratar um indivíduo diagnosticado tanto com hcv quanto com fribose em um mamífero
IT1393841B1 (it) * 2009-04-30 2012-05-11 Giuliani Spa Composizione farmaceutica o dermatologica o nutrizionale o cosmetica per combattere l'azione di immunosoppressione provocata sulla pelle da agenti aggressivi
DE102010025970A1 (de) * 2010-07-02 2012-01-05 Papst Licensing Gmbh & Co. Kg Verfahren zur Bestimmung von Proteasen und ihren Proformen
CN101907614B (zh) * 2010-07-26 2012-05-23 中国科学院长春应用化学研究所 超高效液相色谱和质谱联用筛选组织蛋白酶b抑制剂的方法
CN111447940A (zh) 2017-07-17 2020-07-24 科罗拉多大学评议会 预防或治疗由辐射或放射疗法引起的辐射诱发的旁观者效应的组合物和方法

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
Ｆｒｅｅ Ｒａｄｉｃａｌ Ｒｅｓｅａｒｃｈ、２０１４年、Ｖｏｌ．４８、Ｎｏ．１０、ｐｐ．１２４７－１２５５
ＮＡＴＵＲＥ、２０１７年７月１９日、Ｖｏｌ．５４７、ｐｐ．４５８－４６２、ｄｏｉ：１０．１０３８／ｎａｔｕｒｅ２３２８４
ＯＮＣＯＬＯＧＹ ＬＥＴＴＥＲＳ、２０１３年、Ｖｏｌ．６、ｐｐ．４５３－４５９
ＲＡＤＩＯＩＳＯＴＯＰＥＳ、２００５年、Ｖｏｌ．５４、ｐｐ．２３－２５（（２５）－（２７））
ＲＡＤＩＯＴＨＥＲＡＰＹ ＡＮＤ ＯＮＣＯＬＯＧＹ、２０１１年１１月２５日、ＶＯＬ：１０４、ＰＡＧＥＳ：３９５－４００
Ｓｔｕｄｉｅｓ ｉｎ Ｎａｔｕｒａｌ Ｐｒｏｄｕｃｔｓ Ｃｈｅｍｉｓｔｒｙ、２０１６年、Ｖｏｌ．５０、ｐｐ．１７９－２１３
茶研報、２０１２年、Ｖｏｌ．１１３、ｐｐ．１－９
近畿大医誌、２０１２年、Ｖｏｌ．３７、Ｎｏ．３－４、ｐｐ．１９３－２０２

Also Published As

Publication number Publication date
US20230233517A1 (en) 2023-07-27
US11452709B2 (en) 2022-09-27
WO2019018451A3 (en) 2019-03-14
EP3655015A2 (en) 2020-05-27
WO2019018451A2 (en) 2019-01-24
CA3069701A1 (en) 2019-01-24
US12447142B2 (en) 2025-10-21
JP2020527569A (ja) 2020-09-10
CN111447940A (zh) 2020-07-24
EP3655015B1 (en) 2024-02-21
EP3655015A4 (en) 2021-04-07
JP2023093533A (ja) 2023-07-04
US20200155502A1 (en) 2020-05-21

Similar Documents

Publication Publication Date Title
JP7598137B2 (ja) 放射線または放射線療法によって引き起こされた放射線誘発性バイスタンダ効果を防止および治療するための組成物および方法
Deng et al. FUS interacts with HSP60 to promote mitochondrial damage
JP4018884B2 (ja) 脊柱筋萎縮症の治療
US9234038B2 (en) Compositions and method for the diagnosis, prevention and treatment of alzheimer's disease
US20200206344A1 (en) Methods for modulating the interaction between ews-fli1 and baf complexes
US20180338991A1 (en) Nad biosynthesis and precursors for the treatment and prevention of cancer and proliferation
US20210388040A1 (en) Non-canonical swi/snf complex and uses thereof
EP2039367A1 (en) Prophylactic/therapeutic agent for neurodegenerative disease
JP2010233569A (ja) アポトーシスを調節する方法および組成物
US20200222410A1 (en) Nucleocytoplasmic regulator of autophagy-associated transcription factors
AU2003299132A1 (en) P53 binding polypeptide
US10188650B2 (en) Treatment of neurological disorders
WO2005059100A2 (en) Methods and compositions relating to cystatin c
US20220332813A1 (en) Compositions and methods for treatment and prevention of alzheimer's disease
JP5514443B2 (ja) カテコールアミン調節性タンパク質
EP1678326A2 (en) Genes involved in neurodegenerative disorders
US10017765B2 (en) Inhibitors of CACNA1A/ALPHA1A subunit internal ribosomal entry site (IRES) and methods of treating spinocerebellar ataxia type 6
KR102040893B1 (ko) Arl6ip1의 유전성 강직성 하반신마비의 치료 용도
AU2003231196C1 (en) Androgen-regulated PMEPA1 and cancer
JP4530631B2 (ja) 新規タンパク質および癌の予防・治療剤
JP2007523895A (ja) 過剰な免疫グロブリン産生の治療としてのＢｒｉｇｈｔ機能の阻害方法
WO2025259709A1 (en) Therapy of cns disorders
WO2012007740A1 (en) Neurodegenerative disorders
JPWO2005014809A1 (ja) 肝臓ガン特異的ポリペプチド、該ポリペプチドをコードするポリヌクレオチド、及び該ポリペプチドの発現を抑制するｒｎａ分子

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20200409

RD01 Notification of change of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7426

Effective date: 20200409

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210716

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210716

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20210716

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20220525

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220531

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220831

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20220831

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20221206

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230405

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20230405

C11 Written invitation by the commissioner to file amendments

Free format text: JAPANESE INTERMEDIATE CODE: C11

Effective date: 20230418

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20230523

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20230602

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20241122

R150 Certificate of patent or registration of utility model

Ref document number: 7598137

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150